Triple
T19040266
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | GPA |
E465980
|
entity |
| Predicate | treatedWith |
P2367
|
FINISHED |
| Object | rituximab |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: rituximab | Statement: [GPA, treatedWith, rituximab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rituximab Context triple: [GPA, treatedWith, rituximab]
-
A.
Rituxan
chosen
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Ofatumumab
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
C.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
D.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd0359648190bc2a9202c5cf29d2 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5d80054c88190a9d3a49aed504235 |
completed | April 20, 2026, 7:38 a.m. |
Created at: April 10, 2026, 12:02 p.m.